Laronidase (Aldurazyme®)

Aldurazyme (laronidase) is covered for Hurler, Hurler‑Scheie, and Scheie forms of MPS I (only Scheie with moderate–severe symptoms) — milder Scheie disease is not covered — with authorization for up to 12 months. Coverage requires documented deficient α‑L‑iduronidase activity or pathogenic IDUA gene mutation, prescription or consultation by a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, and dosing limited to ≤0.58 mg/kg IV no more than once weekly with supporting clinical records.

"Aldurazyme (laronidase) is indicated for the treatment of individuals with the Hurler or Hurler-Scheie forms of mucopolysaccharidosis type I."

Sign up to see full coverage criteria, indications, and limitations.